Product News Archives | Page 10 of 15 | Aurobindo Pharma USA

Currently Browsing

All Product News

November 30, 2022


Aurobindo Receives FDA Approval for Ursodiol Capsules USP, 300mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Ursodiol Capsules USP, 300mg. Aurobindo Pharma’s Ursodiol Capsules, are an AB-rated generic equivalent to the reference listed drug (RLD), Actigall® Capsules, manufactured by Teva Branded Pharmaceutical Products R&D, Inc. Ursodiol Capsules are […]

November 29, 2022


Aurobindo Receives FDA Approval for Carbidopa and Levodopa Tablets

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Carbidopa and Levodopa Tablets USP, 10mg/100mg, 25mg/100mg, and 25mg/250mg. Aurobindo Pharma’s Carbidopa and Levodopa Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), SINEMET® Tablets, manufactured by ORGANON, LLC. Carbidopa […]

November 29, 2022


Aurobindo Receives FDA Approval for Valganciclovir for Oral Solution, 50mg/mL

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Valganciclovir for Oral Solution, 50mg/mL. Aurobindo Pharma’s Valganciclovir for Oral Solution, are an AB-rated generic equivalent to the reference listed drug (RLD), VALCYTE® for oral solution 50mg/1mL, manufactured by HOFFMANN LA ROCHE […]

October 24, 2022


Aurobindo Pharma USA, Inc. Initiates Voluntary Nationwide Recall of Two (2) Lots of Quinapril and Hydrochlorothiazide Tablets USP 20mg/12.5mg, due to the detection of N-Nitroso Quinapril Impurity.

Aurobindo Pharma USA, Inc.: Contact 1-866-850-2876 (Option 2) Recall being handled by Qualanex: Contact 1-888-504-2014 FOR IMMEDIATE RELEASE – October 28, 2022– East Windsor, New Jersey, Aurobindo Pharma USA, Inc. has initiated a voluntary recall of two (2) lots (refer table below) of combination project, Quinapril and Hydrochlorothiazide Tablets USP 20mg / 12.5mg, to the […]

September 26, 2022


Aurobindo Receives FDA Approval for Dicloxacillin Sodium Capsules USP, 250mg and 500mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Dicloxacillin Sodium Capsules USP, 250mg and 500mg. Aurobindo Pharma’s Dicloxacillin Sodium Capsules are an AB-rated generic equivalent to the reference listed drug (RLD), Pathocil® Capsules, manufactured by Wyeth Ayerst Laboratories. Dicloxacillin Sodium […]

May 23, 2022


Aurobindo Receives FDA Approval for Exemestane Tablets USP, 25 mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Exemestane Tablets USP, 25 mg.  Aurobindo Pharma’s Exemestane Tablets are an AB-rated generic equivalent to the reference listed drug (RLD), AROMASIN® tablets, manufactured by Pfizer Inc, USA.   Exemestane Tablets are indicated for: […]

May 10, 2022


Aurobindo Receives FDA Approval for Vigabatrin Tablets USP, 500 mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Vigabatrin Tablets USP, 500 mg.  Aurobindo Pharma’s Vigabatrin Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), SABRIL® tablets, manufactured by Lundbeck Pharmaceuticals LLC.  Vigabatrin Tablets are indicated for: Adjunctive […]

April 01, 2022


Aurobindo Receives FDA Approval for Acyclovir Oral Suspension USP, 200 mg/5 mL

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Acyclovir Oral Suspension USP, 200 mg/5 mL. Aurobindo Pharma’s Acyclovir Oral Suspension, are an AB-rated generic equivalent to the reference listed drug (RLD), ZOVIRAX ® (acyclovir), of Mylan Pharmaceuticals Inc. Acyclovir Oral Suspension […]

March 29, 2022


Aurobindo Receives FDA Approval for Bromfenac Ophthalmic Solution 0.09%

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Bromfenac Ophthalmic Solution 0.09%. Aurobindo Pharma’s Bromfenac Ophthalmic Solution, are an AT-rated generic equivalent to the reference listed drug (RLD), Bromday™ Ophthalmic Solution, of Bausch & Lomb. Bromfenac Ophthalmic Solution are indicated for: Postoperative inflammation and reduction of […]

March 28, 2022


Aurobindo Receives FDA Approval for Clobazam Oral Suspension, 2.5 mg/mL

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Clobazam Oral Suspension, 2.5mg/mL. Aurobindo Pharma’s Clobazam Oral Suspension, are an AB-rated generic equivalent to the reference listed drug (RLD), ONFI® Oral Suspension, of Lundbeck Pharmaceuticals LLC . Clobazam Oral Suspension  are […]

January 12, 2022


Aurobindo Receives FDA Approval for Colchicine Tablets USP, 0.6mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Colchicine Tablets USP, 0.6 mg. Aurobindo Pharma’s Colchicine Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), COLCRYS® Tablets, of Takeda Pharmaceuticals USA, Inc. Colchicine Tablets are indicated in: […]

January 12, 2022


Aurobindo Receives FDA Approval for Nebivolol Tablets, 2.5mg, 5mg, 10mg, and 20mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Nebivolol Tablets, 2.5mg, 5mg, 10mg, and 20mg . Aurobindo Pharma’s Nebivolol Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Bystolic® Tablets, of Allergan Sales, LLC. Nebivolol Tablets are […]